Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;31(1):143-156.
doi: 10.1016/j.hoc.2016.08.005.

Advances in Small Cell Lung Cancer

Affiliations
Review

Advances in Small Cell Lung Cancer

Gregory P Kalemkerian et al. Hematol Oncol Clin North Am. .

Abstract

Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor characterized by early metastatic spread and responsiveness to initial therapy. The incidence of SCLC has been declining in the United States in parallel with the decreasing prevalence of cigarette smoking. Limited stage disease is potentially curable with chemoradiotherapy followed by cranial irradiation. Extensive stage disease is incurable, but systemic chemotherapy can improve quality of life and prolong survival. Nearly all patients relapse with chemoresistant disease. Molecularly targeted therapy has failed to yield convincing clinical benefits. Nevertheless, many biologically rational strategies, including immune checkpoint inhibition, show promise in ongoing clinical trials.

Keywords: Chemotherapy; Genomics; Immunotherapy; Lung cancer; Radiation therapy; Small cell; Targeted therapy.

Similar articles

See all similar articles

Cited by 17 articles

See all "Cited by" articles
Feedback